On October 1, Tempus AI fell 5.07% in regular trading, trading at $77.57 per share, with turnover of approximately $203 million.

The decline was primarily driven by persistent large-scale share disposals by CEO and Chairman Eric Lefkofsky. On September 22, Lefkofsky sold approximately 726,400 shares across multiple transactions at prices ranging from $76.57 to $78.86. This followed a separate sale of 199,000 shares on September 17 at $80.00–$81.26 per share. Over the past three months, Lefkofsky has cumulatively sold over 680,000 shares through affiliated entities under a pre-established Rule 10b5-1 trading plan.

Compounding the pressure, several major investment banks recently initiated coverage with neutral ratings and target prices below recent trading levels. Goldman Sachs set a $75 target, UBS at $70, and Rothschild at $67, reinforcing market concerns that the stock is trading at stretched valuations. Cantor Fitzgerald was comparatively more constructive, initiating at overweight with an $80 target, while FactSet consensus stands at a mean target of approximately $67.94.

Tempus AI operates as an AI-driven precision medicine data platform offering genomic sequencing, clinical data analytics, and clinical trial matching services to healthcare providers and pharmaceutical companies.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)